The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Real-world outcomes of second-line ramucirumab plus paclitaxel in patients with advanced gastric or gastroesophageal junction adenocarcinoma: A nationwide retrospective study in Korea (KCSG-ST19-16).
 
Dae Young Zang
No Relationships to Disclose
 
Hye Sook Han
No Relationships to Disclose
 
Bum Jun Kim
No Relationships to Disclose
 
Hee-Jung Jee
No Relationships to Disclose
 
Young Ju Suh
No Relationships to Disclose
 
Hyonggin An
No Relationships to Disclose
 
Ji-Hye Byun
No Relationships to Disclose
 
Dong Sook Kim
No Relationships to Disclose
 
Se Hoon Park
Consulting or Advisory Role - Janssen Oncology; Lilly
Research Funding - Ono Pharmaceutical
 
Sun Young Rha
Consulting or Advisory Role - Amgen; Daiichi Sankyo; Eisai; Indivumed; Ipsen; MSD Oncology
Speakers' Bureau - Eisai; Eisai; Lilly
Research Funding - ASLAN Pharmaceuticals; Bayer; Bristol-Myers Squibb; Eisai; Immunomet; medpacto; MSD Oncology; Roche/Genentech; Sillajen
 
Do-Youn Oh
Consulting or Advisory Role - ASLAN Pharmaceuticals; AstraZeneca; Basilea; Bayer; BeiGene; Celgene; Genentech/Roche; Halozyme; Merck Serono; Novartis; Taiho Pharmaceutical; Zymeworks
Research Funding - Array BioPharma; AstraZeneca; BeiGene; Lilly; MSD; Novartis; SERVIER
 
Jong Gwang Kim
No Relationships to Disclose
 
Woo Kyun Bae
No Relationships to Disclose
 
In-Ho Kim
No Relationships to Disclose
 
Sun Jin Sym
No Relationships to Disclose
 
So Yeon Oh
No Relationships to Disclose
 
Hyeong Su Kim
No Relationships to Disclose
 
Keun Wook Lee
Honoraria - BMS; Genexine; Lilly
Consulting or Advisory Role - Bayer; ISU ABXIS
Research Funding - ABL Bio (Inst); ALX Oncology (Inst); Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); BeiGene (Inst); Daiichi Sankyo (Inst); Five Prime Therapeutics (Inst); Green Cross (Inst); LSK BioPharma (Inst); Macrogenics (Inst); Merck KGaA (Inst); MSD (Inst); Oncologie (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Pharmacyclics (Inst); Taiho Pharmaceutical (Inst); Y-BIOLOGICS (Inst); Zymeworks (Inst)
 
Min-Hee Ryu
Honoraria - Bristol-Myers Squibb; DAEHWA Pharmaceutical; Lilly; MSD; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - Bristol-Myers Squibb; DAEHWA Pharmaceutical; Lilly; MSD; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical